Literature DB >> 19189202

Mitotic drivers--inhibitors of the Aurora B Kinase.

Nicholas Keen1, Stephen Taylor.   

Abstract

In this article we review the basis for current anti-mitotic, anti-cancer, therapy and the potential for Aurora B kinase inhibitors as a new differentiated class of agents--"mitotic drivers". We review the current understanding of Aurora B inhibition from basic cell biology to inhibitors currently undergoing clinical trials.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19189202     DOI： 10.1007/s10555-009-9184-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  31 in total

1.  Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Authors:  Gary K Schwartz; Richard D Carvajal; Rachel Midgley; Scott J Rodig; Paul K Stockman; Ozlem Ataman; David Wilson; Shampa Das; Geoffrey I Shapiro
Journal:  Invest New Drugs       Date:  2012-06-02       Impact factor: 3.850

Review 2.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

3.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

Review 4.  The potential role of Aurora kinase inhibitors in haematological malignancies.

Authors:  Sherif S Farag
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

5.  Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Authors:  Andrew J Holland; Don W Cleveland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

6.  Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Raghavendra Gowda; Arthur Berg; Rogerio I Neves; Gavin P Robertson
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

7.  Update on Aurora Kinase Targeted Therapeutics in Oncology.

Authors:  Myke R Green; Joseph E Woolery; Daruka Mahadevan
Journal:  Expert Opin Drug Discov       Date:  2011-03       Impact factor: 6.098

Review 8.  Update on aurora kinase inhibitors in gynecologic malignancies.

Authors:  Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-11       Impact factor: 4.169

Review 9.  Coordinating cellular events during spermatogenesis: a biochemical model.

Authors:  Pearl P Y Lie; C Yan Cheng; Dolores D Mruk
Journal:  Trends Biochem Sci       Date:  2009-06-15       Impact factor: 13.807

10.  Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.

Authors:  Hagop M Kantarjian; Mikkael A Sekeres; Vincent Ribrag; Philippe Rousselot; Guillermo Garcia-Manero; Elias J Jabbour; Kate Owen; Paul K Stockman; Stuart D Oliver
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.